Tuesday | Wednesday | Thursday | Friday | Saturday
7:00 am - 5:15 pm Registration - Bridge Hall
7:30 am - 9:00 am

POSTER SESSION 4 & continental breakfast – Halls A-B




Breast Imaging - Mammography

Breast Imaging - MRI

Breast Imaging - Other Methods





Tumor Cell and Molecular Biology


Immunology and Preclinical Immunotherapy

Systems Biology of Breast Cancer


DNA Damage and Repair

Cellular Mechanisms









Psychosocial, Quality of Life, and Educational Aspects


Survivorship Research

Psychosocial, QOL, and Educational Aspects - Other




Adjuvant Therapy - Targeted

Advanced Therapy - Targeted

HER2-Targeted Therapy




9:00 am - 9:30 am



Systemic Therapy of HER2 Positive Breast Cancer

Mothaffar Rimawi, MD

Baylor College of Medicine

Houston, TX

9:30 am - 11:30 am


9:30 am

S5-01. Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies
Pusztai L, Shi W, Jiang T, Nuciforo P, Holmes E, Harbeck N, Sotiriou C, Rimm D, Hatzis C, de la Peña L, Armour A, Piccart-Gebhart M, Baselga J. Yale University, New Haven, CT; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Frontier Science (Scotland) Ltd; University of Munich; Jules Bordet Institute and Memorial Sloan Kettering Cancer Center; SOLTI Clinical Trial Group; Novartis.

9:45 am

S5-02. Neratinib after trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: 3-year analysis from a phase 3 randomized, placebo-controlled, double-blind trial (ExteNET)
Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harker G, Masuda N, Neskovic Konstantinovic ZB, Petrakova K, Guerrero Zotano AL, Iannotti N, Rodriguez GI,  Tassone P, von Minckwitz G, Ejlertsen B, Chia SKL, Mansi J, Barrios CH, Buyse M, Wong A, Bryce R, Ye Y, Martin M. Mount Medical Centre, Mount Hospital, Australia; Institut Gustave Roussy, France; Texas Oncology, PA; Massachusetts General Hospital; Aichi Cancer Center, Japan; Utah Cancer Specialists; National Hospital Organization Osaka National Hospital, Japan; Institute of Oncology and Radiology of Serbia Pasterova 14, Serbia; Masarykuv Onkologicky Ustav, Czech Republic; Instituto Valenciano de Oncologia, Spain; Hematology Oncology Associates of Treasure Coast; STOH Research - South Texas Oncology and Hematology; Tammaso Campanella Cancer Center, Italy; GBG Forschungs GmbH; Luisenkrankenhaus, Germany; Rigshospitalet, Denmark; British Columbia Cancer Agency, Canada; Guy's Hospital, United Kingdom; PUCRS School of Medicine, Brazil; IDDI & CluePoints, United States; Puma Biotechnology Inc.; Hospital General Universitario Gregorio Marañón, Spain.

10:00 am

S5-03. Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer

Harbeck N, Gluz O, Christgen M, Braun M, Kuemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, Liedtke C, Kates RE, Wuerstlein R, de Haas SL, Kiermaier A, Kreipe HH, Nitz U.  Westdeutsche Studiengruppe GmbH, Moenchengladbach, Germany; Breast Center, University of Munich and CCCLMU; Ev. Hospital Bethesda, Breast Center Niederrhein; Medical School Hannover, Institute of Pathology; Rotkreuz Clinic Munich; Clinics Essen-Mitte, Breast Center; St. Elisabeth Hospital Cologne; Ev. Waldkrankenhaus Berlin; University Clinic Cologne, Breast Center; DRK Clinic Berlin Koepenick, Breast Center; Clinic Deggendorf; University Clinic Essen, Women's Clinic; Practice Network Troisdorf; University Clinic Muenster, Women's Clinic; University Clinics Schleswig-Holstein/Campus Luebeck, Women’s Clinic; Palleos Healthcare Services, Statistics; F. Hoffmann - La-Roche.

10:15 am

S5-04. Ten year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC®T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer patients
Slamon DJ, Eiermann W, Robert NJ, Giermek J, Martin M, Jasiowka M, Mackey JR, Chan A, Liu M-C, Pinter T, Valero V, Falkson C, Fornander T, Shiftan TA, Bensfia S, Hitier S, Xu N, Bée-Munteanu V, Drevot P, Press MF, Crown J.  UCLA, Los Angeles, CA; GBG, Munchen, Germany; USO, The Woodlands, TX; Maria Sklodowska-Curie Centre, Warsaw, Poland; GEICAM, Madrid, Spain; Maria Sklodowska-Curie Memorial Cancer Institute, Krakow, Poland; Cross Cancer Institute, Edmonton, Canada; Breast Cancer Research Centre - WA & Curtin University, Perth, Australia; Sun Yat-Sen Cancer Center, Taipei, Taiwan; Petz Aladar Megyei Oktato Korhaz Onkoradiologica, Gyor, Hungary; The University of Texas MD Anderson Cancer Centre, Houston, TX; University of Alabama, Birmingham, AL; Karolinska University Hospital, Stockholm, Sweden; Sharp Memorial Hospital, San Diego, CA; Sanofi, Cambridge; Sanofi, Chilly-Mazarin, France; Genentech, South San Francisco, CA; TRIO, Paris, France; USC/ Norris Comprehensive Cancer Center, Los Angeles, CA; ICORG, Dublin, Ireland. 

10:30 am

S5-05.  Trastuzumab emtansine improves overall survival versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study

Wildiers H, Kim S-B, Gonzalez-Martin A, LoRusso PM, Ferrero J-M, Yu R, Smitt M, Krop I. University Hospitals Leuven, Leuven, Belgium; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Centro Oncológico MD Anderson International España, Madrid, Spain; Yale Cancer Center, Yale University Medical Center, New Haven, CT; Centre Antoine Lacassagne, Nice, France; Genentech, Inc, South San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA.

10:45 am

S5-06.  BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study

Fasching PA, Loibl S, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm TN, Huober J, Liedtke C, Müller V, Nekljudova V, Weber K, Rack B, Rübner M, Wang L, Ingle JN, Weinshilboum RM, von Minckwitz G, Couch F.  University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; GBG Forschungs GmbH, Neu Isenburg, Germany; Christian-Albrechts-University, Kiel, Germany; CHOP Onkologie Bethanien, Frankfurt, Germany; Eilenriede-Klinik, Hannover, Germany; Breast Center of Düsseldorf, Luisenkrankenhaus, Düsseldorf, Germany; University of Rostock, Rostock, Germany; Magdeburg University Hospital, Magdeburg, Germany; University of Ulm, Ulm, Germany; Heinrich-Heine-University, Düsseldorf, Germany; Charite, Berlin, Germany; Lübeck University Hospital, Lübeck, Germany; Hamburg University Hospital, Hamburg, Germany; Ludwig Maximilian University, Munich, Germany; Division of Clinical Pharmacology, Mayo Clinic College of Medicine, Mayo Medical School–Mayo Foundation, Rochester, MN; Mayo Clinic Rochester, Rochester, MN; Division of Experimental Pathology, Mayo Clinic, Rochester, MN.

11:00 am

S5-07.   Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028

Rugo HS, Delord J-P, Im S-A, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Le Tourneau C, van Brummelen E, Varga A, Saraf S, Pietrangelo D, Karantza V, Tan A. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institut Universitaire du Cancer, Toulouse, France; Seoul National University Hospital, Seoul, Republic of Korea; Dana-Farber Cancer Institute, Boston, MA; The University of Texas MD Anderson Cancer Center, Houston, TX; Princess Margaret Cancer Centre, Toronto, ON, Canada; Honor Health, Scottsdale, AZ; Institut Curie, Paris, France; Netherlands Cancer Institute, Amsterdam, Netherlands; Gustave Roussy, Villejuif, France; Merck & Co., Inc., Kenilworth, NJ; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

11:15 am

S5-08. Late side-effects of breast cancer radiotherapy: Second cancer incidence and non-breast-cancer mortality among 40,000 women in 75 trials

Taylor C, Correa C, Anderson S, Duane F, Ewertz M, Jagsi R, Pierce L, Swain S, Whelan T, Wang Z, Wang Y, Peto R, McGale P.  NDPH Clinical Trial Service Unit, Oxford University, Oxford, United Kingdom; Cancer Centre and Research Institute University of Southern Florida, Tampa, FL; University of Pittsburgh, Pittsburgh, PA; Odense University Hospital, Odense, Denmark; University of Michigan, MI; Washington Cancer Institute MedStar Washington Hospital Center, WA; McMaster University and Juravinski Cancer Centre, Ontario, Canada.

11:30 am - 12:00 pm

AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen® - Hall D


Breast Tumor Heterogeneity: Act Locally, Think Globally
Mohamed Bentires-Alj, Pharm. PhD
Friedrich Miescher Institute for Biomedical Research (FMI)

12:00 pm - 1:00 pm LUNCH AND EXHIBITS
1:00 pm - 2:00 pm


  Moderator: Mothaffar Rimawi, MD, Baylor College of Medicine, Houston, TX

Sunil Badve, MBBS
Indiana University
Indianapolis, IN

Christine Benjamin, MSW
New York, NY

Roshni Rao, MD
UT Southwestern Medical Center
Dallas, TX

Hope S. Rugo, MD
University of California San Francisco
San Francisco, CA

Nicholas Turner, BM Bch
Royal Marsden and Institute for Cancer Research

Wendy A. Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX
1:00 pm - 2:00 pm BASIC SCIENCE FORUM - Ballroom B

Targeting Mitochondrial Dysfunction in Breast Cancer

Moderator: Michael T. Lewis, PhD, Baylor College of Medicine, Houston, TX

Dominance of mitochondria in determining the malignant phenotype

Benny Abraham Kaipparettu, M-Pharm, PhD

Baylor College of Medicine

Houston, TX

Targeting mitochondria with FDA-approved antibiotics may be a new therapeutic strategy to eliminate cancer stem cells

Michael Lisanti, MD-PhD

University of Manchester


2:15 pm - 3:15 pm



Precision Medicine by Sequencing: Is it Ready for Common Clinical Use?

Moderator: Charles M. Perou, PhD, University of North Carolina, Chapel Hill, NC

Defining the actionable genome

Gordon B. Mills, MD, PhD

The University of Texas MD Anderson Cancer Center

Houston, TX

Genomics to personalize therapy of metastatic breast cancers

Fabrice André, MD, PhD

Institut Gustave Roussy

Villejuif, FRANCE

3:15 pm - 5:00 pm


3:15 pm

S6-01. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, Phase III BELLE-2 trial
Baselga J, Im S-A, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng L-M, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Hachemi S, Le Mouhaër S, Di Tomaso E, Urban P, Massacesi C, Campone M. Memorial Sloan Kettering Cancer Center, New York, NY; Seoul National University College of Medicine, Seoul, Republic of Korea; Aichi Cancer Center, Nagoya, Japan; Ottawa Hospital Research Institute, Ottawa, Canada, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan, Institut Jules Bordet, Brussels, Belgium; BC Cancer Agency, Vancouver, Canada, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, Poland, Ospedale di Macerata, Macerata, Italy, Taipei Veterans Gereral Hospital, Taipei, Taiwan; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; National Hospital Organization Osaka National Hospital, Osaka, Japan; Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy; Vanderbilt-Ingram Cancer Center, Nashville, TN; Beijing 307 Hospital of PLA, Beijing, China; University Hospital Schleswig-Holstein, Kiel, Germany; Novartis Pharma S.A.S., Paris, France; Novartis Institutes for BioMedical Research, Cambridge, MA; Novartis Pharma AG, Basel, Switzerland; Institut de Cancérologie de l’Ouest, René Gauducheau Centre de Recherche en Cancérologie, Nantes, France.

3:30 pm

S6-02. Occurrence of natural ESR1 mutations during acquisition of endocrine resistance in breast cancers and widely used ER+ cell lines
Gellert P, Ribas R, Pancholi S, Lopez-Knowles E, Yeo B, Garcia-Murillas I, Pearson A, Smith I, Turner N, Dowsett M, Martin LA. Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom.

3:45 pm

S6-03.  Anastrozole versus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (IBIS-II DCIS)

Cuzick J, Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I. University of Newcastle, Calvary Mater Hospital, Australia New Zealand Breast Cancer Trials Group Newcastle, Newcastle, Australia; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, London, United Kingdom; Genesis Breast Cancer Prevention Centre, Manchester, United Kingdom; Instituto Europeo di Oncologia, Milan, Italy; South Manchester University Hospital, Manchester, United Kingdom; Centre François Baclesse, Caen, France; German Breast Group, Neu-Isenburg, Germany; Interdisciplinary Oncology Center München, Munich, Germany; UZ Gasthuisberg Ziekenhuis, Leuven, Belgium; Vienna International Health Centre, Vienna, Austria; Royal Liverpool University Hospital, Liverpool, United Kingdom; Weston Park Hospital, Sheffield, United Kingdom; Barts Cancer Institute, John Vane Science Centre, London, United Kingdom; University of Nottingham, Molecular Medical Sciences, Nottingham, United Kingdom.

4:00 pm

S6-04. Patient-reported outcome (PRO) results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) vs tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy
Ganz PA, Cecchini RS, Julian TB, Margolese RG, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky A, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. NSABP/NRG Oncology; UCLA Schools of Medicine and Public Health and Jonsson Comprehensive Cancer Center; University of Pittsburgh; Allegheny Cancer Center at Allegheny General Hospital; Jewish General Hospital, McGill University; NRG Oncology Statistics and Data Management Center (SDMC); Mayo Clinic; Loyola University Chicago Cardinal Benardin Cancer Center; Nashville Breast Center; Fox Chase and Northwestern (ECOG); Magee-Women's Hospital, University of Pittsburgh; Dayton NCORP; Missouri Valley Cancer Consortium; Novant Health; Kaiser Permanente Northern California; Colorado Cancer Research Program; Christiana Care CCOP; Atlanta Regional CCOP; UF Health Cancer Center at Orlando Health.

4:15 pm

S6-05.  A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC)
Ma CX, Gao F, Northfelt D, Goetz M, Forero A, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Hoog J, Han J, Guo Z, Vij K, Mardis E, Al-Kateb H, Sanati S, Ellis MJ. Washington University, Saint Louis, MO; Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Rochester, MN; University of Alabama at Birmingham, Birmingham, AL; Baylor College of Medicine, Houston, TX. 

4:30 pm

Moved from PD5-02
S6-06. The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

van Ramshorst MS, van der Heijden-van der Loo M, Dackus GMHE,
Linn SC, Sonke GS.  Netherlands Cancer Institute, Amsterdam, Netherlands; Comprehensive Cancer Organisation, Utrecht, Netherlands.

Mette Susanne van Ramshorst, MD is a recipient of a SABCS Clinical Scholar Award.

4:45 pm

Moved from P1-13-01
S6-07. Comparison of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial

Gluz O, Nitz U, Liedtke C, Christgen M, Sotlar K, Grischke E, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kümmel S, Clemens M, Potenberg J, Staib P, Kohls A, Kates RE, Würstlein R, Kreipe H, Harbeck N.  Westdeutsche Studiengruppe GmbH, Moenchengladabach, Germany; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; University Clinics Schleswig-Holstein/Campus Luebeck, Women's Clinic; Medical School Hannover, Institute of Pathology; University of Munich (LMU), Institue of Pathology; University Clinics Tuebingen, Women's Clinic; Practice Network Troisdorf; Rotkreuz Clinics Munich; Clinics of Cologne - Hospital Holweide; Marien-Hospital Witten; Gynecologic Oncologic Practice Hildesheim; University Clinics Essen, Women's Clinic; St. Elisabeth Hospital Cologne; Charité Berlin, Clinic of Gynecology; Agaplesion Diakonie Clinic; Clinics Essen-Mitte, Breast Center; Mutterhaus der Borromäerinnen Trier; Ev. Waldkrankenhaus; St. Antonius Hospital, Clinicsof Hematology and Oncology; Ev. Hospital Ludwigsfelde; Pathology Viersen; Palleos Healthcare Services, Statitistics; Breast Center, University of Munich and CCCLMU.
5:00 pm - 7:00 pm

POSTER DISCUSSION 6: Translational Genomics - Ballroom B

  Nicholas Turner, BM Bch, Co-Discussant
Royal Marsden and Institute of Cancer Research
Nikhil Wagle, MD, Co-Discussant
Dana-Farber Cancer Institute
Boston, MA
5:00 pm - 7:00 pm

POSTER DISCUSSION 7: Clinical Applications of Hereditary Multigene Panels - Ballroom A

  Beth Crawford, MC, LCGC, Co-Discussant
UCSF Cancer Genetics and Prevention Program
San Francisco, CA
Judy E. Garber, MD, MPH, BA, Co-Discussant
Dana-Farber Cancer Institute
Boston, MA
5:00 pm - 7:00 pm

POSTER SESSION 5 & reception - Hall A-B




Molecular, Functional, and Novel Imaging

Detection/Diagnosis - Other




Tumor Cell and Molecular Biology


New Drugs and Mechanisms

Novel/Emerging Therapeutics Targets

Metabolism and Breast Cancer







Prognostic and Predictive Factors


Biomarkers - Methods

Prognostic and Predictive Factors - Other



  Psychosocial, Quality of Life, and Educational Aspects  



Doctor-Patient Communication





Adjuvant Endocrine Therapy

Neoadjuvant Endocrine Therapy

Advanced Endocrine Therapy

Adjuvant Therapy - Other

Advanced Therapy - Other


Clinical Trials Design and Management









Ongoing Clinical Trials 3








Tuesday | Wednesday | Thursday | Friday | Saturday